On Monday, the Danish drugmaker said it had agreed to pay up to $2 billion for the rights to an experimental drug from the Chinese pharmaceutical company United Laboratories International. The injectable treatment – UBT251 – is in early development to treat obesity, Type 2 diabetes and other conditions, so it could take several years before it enters any market.